Literature DB >> 8249001

The Stroke Prevention Patient Outcomes Research Team. Goals and methods.

D B Matchar1, P W Duncan, G P Samsa, J P Whisnant, G H DeFriese, D J Ballard, J E Paul, D M Witter, J P Mitchell.   

Abstract

BACKGROUND AND
PURPOSE: The aim of the present study, based at Duke University and involving 14 other institutions, is to identify the most appropriate and cost-effective clinical strategies for prevention of ischemic (thrombotic or embolic) stroke in high-risk individuals and to design and test an intervention to disseminate this information to providers and the public.
METHODS: The study uses (1) secondary data from literature review, Medicare claims, and population-based data from three epidemiological studies and (2) primary data generated in national physician and patient surveys and in demonstration trials. Phases I through III involve data collection and analysis using a decision/cost-effectiveness model and consensus development methods. Phase IV includes intervention in physicians' practice patterns. Data is collected by literature survey and abstraction, review of medical records, claims analysis, and patient and physician surveys.
CONCLUSIONS: A structured decision model and a well-defined clinical focus provide a successful organization for a PORT on stroke prevention.

Entities:  

Mesh:

Year:  1993        PMID: 8249001     DOI: 10.1161/01.str.24.12.2135

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  2 in total

1.  Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients.

Authors:  Per-Henrik Zingmark; Marianne Ekblom; Tomas Odergren; Tim Ashwood; Patrick Lyden; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

2.  Stroke unit care: recurrence, mortality and institutionalisation rates-a four year follow-up study.

Authors:  T Walsh; T Donnelly; S Carew; C O' Connor; R O' Riordan; D Lyons
Journal:  Ir J Med Sci       Date:  2007-12-18       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.